HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

romidepsin (FK228)

a bicyclic depsipeptide and a potent histone deacetylase inhibitor from Chromobacterium violaceum; structure in first source

Also Known As:

FK228; FR901228; FR 901228; FR-901228; istodax; L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-

Networked: 291 relevant articles (29 outcomes, 91 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bates, Susan E: 24 articles (07/2015 - 03/2002)
2.	Piekarz, Richard L: 16 articles (07/2015 - 03/2002)
3.	Prince, H Miles: 12 articles (07/2015 - 11/2009)
4.	Figg, William D: 11 articles (08/2013 - 03/2002)
5.	Nichols, Jean: 8 articles (08/2015 - 01/2009)
6.	Fojo, Tito: 8 articles (07/2015 - 03/2002)
7.	Steinberg, Seth M: 8 articles (07/2015 - 06/2006)
8.	Robey, Robert W: 8 articles (05/2015 - 03/2002)
9.	Frye, Robin: 7 articles (08/2013 - 02/2009)
10.	Wright, John J: 7 articles (12/2012 - 06/2006)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2014 - "Our in vitro study suggested that combination of FK228 and RXM may be helpful for enhancing tumor killing effects. " 05/15/2015 - "In a phase I study published in Clinical Cancer Research in March 2002, romidepsin (depsipeptide), a potent HDAC inhibitor, was found to be tolerable, with a side effect profile that was later understood to be characteristic of this class of agents. " 08/15/2013 - "Although there were no objective responses with romidepsin alone, this schedule may be useful for developing combination studies in solid tumors." 08/15/2013 - "Phase I trial of a new schedule of romidepsin in patients with advanced cancers." 12/01/2012 - "A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa. "
2.	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 02/20/2012 - "The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). " 02/01/2014 - "Romidepsin is effective and well-tolerated in patients ≥60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): analysis from phase 2 trials." 01/01/2014 - "Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses." 02/20/2012 - "Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy." 06/02/2011 - "Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma."
3.	T-Cell Lymphoma (Lymphoma, T Cell) 08/01/2011 - "As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few effective therapies." 08/01/2013 - "These initial results observed with single-agent romidepsin provide a foundation for exploring combination strategies and demonstrates proof-of-principle that other such drugs with similar mechanisms of action may be effective in T-cell lymphoma. " 05/16/2013 - "Gene expression analysis of samples obtained from patients with CTCL enrolled on the NCI1312 phase 2 study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathway by romidepsin. " 12/01/2010 - "The efficacy and safety profile of romidepsin in clinical trials in T-cell lymphoma is reviewed, and emerging data on single-agent and combination strategies in myeloid and B-lymphoid malignancies is outlined. " 11/10/2009 - "On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. "
4.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 10/10/2010 - "The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL). " 12/01/2013 - "Based on two large Phase II studies, the US FDA approved intravenous romidepsin for patients with relapsed/refractory cutaneous T-cell lymphomas. " 10/01/2012 - "Phase 1 and 2 trials evaluating the efficacy and safety of romidepsin were reviewed with a specific focus on its use in cutaneous T-cell lymphoma. " 10/10/2010 - "Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma." 10/01/2015 - "Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma."
5.	Pruritus (Itching) 10/10/2010 - "Romidepsin has significant and sustainable single-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an important therapeutic option for treatment refractory CTCL." 10/01/2012 - "Romidepsin has shown an improvement in duration of response and pruritus over traditional therapy. " 02/01/2013 - "In a phase 2 study of romidepsin in patients with CTCL (GPI-04-0001), clinically meaningful reduction in pruritus (CMRP) was evaluated as an indicator of clinical benefit by using a patient-assessed visual analog scale. " 02/01/2013 - "Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin." 02/01/2013 - "To determine the effect of romidepsin alone, confounding pruritus treatments including steroids and antihistamines were prohibited. "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	romidepsin (FK228)
3.	vorinostat (suberoylanilide hydroxamic acid)
4.	bortezomib (Velcade)
5.	decitabine (5-aza-2'-deoxycytidine)
6.	Asp(5)- oxytocin (OXA)
7.	gemcitabine
8.	Vincristine (Oncovin)
9.	Cyclophosphamide (Cytoxan)
10.	docetaxel (Taxotere)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Drug Therapy (Chemotherapy)
3.	Castration
4.	Stents
5.	Homologous Transplantation (Allograft)